Enovis Corporation
ENOVHealthcareNASDAQMedical Devices · Last scanned Sep 9, 2026
Scan Results
Daily timeframeEnovis Corporation, a medical technology company, focuses on developing clinically differentiated solutions in the United States and internationally. At a $1.15B market cap, Enovis Corporation ranks as a small-cap company within healthcare. It operates through two segments: Prevention and Recovery, and Reconstructive segments.
Market Cap
$1.15B
Beta
1.43
P/E (TTM)
—
P/E (Fwd)
5.41
EPS (TTM)
$-19.27
EPS (Fwd)
$3.69
ROE
-54.1%
ROA
1.2%
Cash
$12.6M
Total Debt
$1.37B
Free CF
$185.6M
52W Change
-39.1%
Annual Financials
Cash vs Debt
Where ENOV stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, ENOV finished 16.39% below its 150-day moving average ($24.16) and 18.65% below its 200-day moving average ($24.83). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is ENOV overbought or oversold?
At the September 3, 2026 close, ENOV's RSI(14) was 24.4, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Enovis Corporation carries $1.37B in total debt against $12.6M in cash reserves — debt is roughly 109.0x the cash position. Managing this leverage effectively will be important for long-term financial stability. Annual free cash flow of $185.6M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. Return on equity stands at -54.1%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. ROA of 1.2% is on the lower side, which is common in asset-heavy industries. Revenue has grown from $1.56B (2022) to $2.25B (2025), reflecting a 44% increase over the period.
Enovis Corporation carries a heavier debt load relative to its cash position, which introduces financial risk that investors should weigh. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Enovis Corporation's trajectory.